Literature DB >> 20156036

In vitro inhibition of low density lipoprotein carbamylation by vitamins, as an ameliorating atherosclerotic risk in uremic patients.

Mohammad Ali Ghaffari1, Mehrnoosh Shanaki.   

Abstract

INTRODUCTION: Previous studies have shown that the increase of carbamylated LDL (cLDL), a product of nonenzymatic modification of LDL in human serum by urea-derived cyanate, may cause cardiovascular complications in patients with chronic renal insufficiency. This study examined the inhibitory effect of ascorbic acid, alpha-tocopherol and lycopene on LDL carbamylation in an in vitro model system.
METHODS: After isolation of LDL from plasma using an ultracentrifuge technique, cyanate was added to it and then LDL carbamylation was measured in both the absence and presence of ascorbic acid, alpha-tocopherol and/or lycopene by the colorimetric method at 530 nm.
RESULTS: The findings indicated that these vitamins inhibit LDL carbamylation and the most effective vitamin of the three is lycopene. Moreover, the effect of lycopene on this process increased in the presence of ascorbic acid and alpha-tocopherol.
CONCLUSION: This study indicated that ascorbic acid, alpha-tocopherol and lycopene with antioxidant activity can probably inhibit LDL carbamylation and therefore may have a role in ameliorating atherosclerotic risk of patients with kidney failure. However in vitro and in vivo investigations are required to confirm the exact effects of these vitamins on patients suffering from uremic disorders.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156036     DOI: 10.3109/00365511003624137

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  5 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

Review 2.  Avenues for post-translational protein modification prevention and therapy.

Authors:  Mengyao Tang; Sahir Kalim
Journal:  Mol Aspects Med       Date:  2022-02-25

Review 3.  Protein carbamylation in end stage renal disease: is there a mortality effect?

Authors:  Sahir Kalim
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-11       Impact factor: 2.894

Review 4.  Protein carbamylation and cardiovascular disease.

Authors:  Frederik H Verbrugge; W H Wilson Tang; Stanley L Hazen
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

Review 5.  Carbamylated Proteins in Renal Disease: Aggravating Factors or Just Biomarkers?

Authors:  Laëtitia Gorisse; Stéphane Jaisson; Christine Piétrement; Philippe Gillery
Journal:  Int J Mol Sci       Date:  2022-01-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.